Solving complex problems to meet patients’ needs is our mission—caring deeply about client programs is our nature
BIOVECTRA is a North American CDMO specializing in clinical-to-commercial scale production capabilities for:
Biologics
Synthetic small molecules
pDNA and mRNA
Highly potent APIs
Bioreagents
Our teams, backed by 50+ years of experience and a proven track record of excellence, optimize, adapt, and perfect innovative technologies and drug substance development approaches to deliver world-class solutions for pharmaceutical manufacturing.
We thrive on the vexing challenges few CDMOs would have the expertise or desire to address. Bold vision, along with the passion and commitment to make that vision a reality, is at the heart of our organization.
We care. We care about your projects. We care about quality. We care about innovation. We care about high quality pharmaceutical manufacturing.
Our Team Cares About Your Success
Flexibility, creativity, and dedication to process optimization are at the heart of our work. This is reflected in our method and process development, quality, and compliance efforts. We ensure that programs advance on time and with the highest quality outcomes under our leadership.
“Flexibility is built into our DNA. The ability and dedication to solving our clients’ complex problems, no matter what it takes, is the key to our long-term relationships.”
— Andrew Mitchell, Senior Director Business Development
BIOVECTRA in Numbers
50+
Years of experience
100+
Active clients across five geographic markets
18/20
Top pharma and biotech companies supported
10+
Partnered capacity expansion projects since 2003
Contact Us
Oliver Technow - Chief Executive Officer
Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
More than 20 years of global pharmaceutical industry experience.
Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ; in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
Appointed President of BIOVECTRA Inc., December 10, 2015.
Board Director for BIOTECanada
Member of the Steering Council of Innovative Medicines Canada (IMC)
In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
In November 2019, promoted to Chief Executive Officer at BIOVECTRA
In June 2020, named new Chair of PEI BioAlliance Board of Directors